Versatope Therapeutics
Versatope Therapeutics is a clinical stage biotechnology company leveraging nature’s extracellular transport vesicles to develop vaccines and immuno-therapeutics. Their platform uses molecular engineering of proprietary cell lines to produce Recombinant Extracellular Transport Vesicles (RET-V's) for cross-strain immunity against infectious diseases like influenza and malaria, as well as targeted cancer therapeutics. They focus on designing potent, multi-strain vaccines, delivering therapeutic RNA into cancer cells, and creating thermostable vaccines with rapid synthesis and scale-up capabilities. Their mission is to deliver immunity by harnessing the power of nature in a potent therapeutic delivery platform, aiming to realize a healthier world through immune-based therapeutics.
Industries
Nr. of Employees
small (1-50)
Versatope Therapeutics
Products
Multi-variant vesicle-based influenza vaccine candidate
A vesicle-based vaccine construct engineered to present antigens from multiple influenza strains on a single vesicle; advanced through preclinical efficacy studies and prepared for scale-up and IND-enabling activities with formulations targeting thermostability and extended dosing.
Dual-action vesicle-based malaria vaccine program
Development of a vesicle-based malaria vaccine designed to block both infection and transmission pathways; program supported by government grant funding for further development.
Modular vesicle delivery platform for vaccines and therapeutics
A modular platform for decorating bacterial-derived vesicles with engineered antigens or therapeutic payloads for vaccine and targeted delivery applications; supported by peer-reviewed publications and conference presentations.
Multi-variant vesicle-based influenza vaccine candidate
A vesicle-based vaccine construct engineered to present antigens from multiple influenza strains on a single vesicle; advanced through preclinical efficacy studies and prepared for scale-up and IND-enabling activities with formulations targeting thermostability and extended dosing.
Dual-action vesicle-based malaria vaccine program
Development of a vesicle-based malaria vaccine designed to block both infection and transmission pathways; program supported by government grant funding for further development.
Modular vesicle delivery platform for vaccines and therapeutics
A modular platform for decorating bacterial-derived vesicles with engineered antigens or therapeutic payloads for vaccine and targeted delivery applications; supported by peer-reviewed publications and conference presentations.
Services
End-to-end preclinical development of vesicle-based vaccine and therapeutic candidates, including antigen design, in vivo efficacy testing, formulation development and coordination of GLP safety studies to support IND submissions.
Clinical program planning, protocol development, CRO selection and oversight, and medical monitoring provided by experienced clinical development leads.
Process development services for scalable microbial production, creation of traceable microbial cell lines and master cell banks, and transfer activities to support clinical and GMP manufacturing.
End-to-end preclinical development of vesicle-based vaccine and therapeutic candidates, including antigen design, in vivo efficacy testing, formulation development and coordination of GLP safety studies to support IND submissions.
Clinical program planning, protocol development, CRO selection and oversight, and medical monitoring provided by experienced clinical development leads.
Process development services for scalable microbial production, creation of traceable microbial cell lines and master cell banks, and transfer activities to support clinical and GMP manufacturing.
Expertise Areas
- Vaccine development using extracellular vesicle platforms
- Bacterial extracellular vesicle engineering and surface display
- Targeted therapeutic delivery using vesicle carriers
- Preclinical development and animal challenge efficacy models
Key Technologies
- Recombinant bacterial extracellular vesicles (rOMVs/rEVs)
- Vesicle surface display engineering
- Vesicle-mediated nucleic acid and protein delivery
- Controlled-release and sustained-release formulation technologies
News & Updates
Versatope received a Phase 2 SBIR grant from NIH for up to $3 million to develop a bi-specific malaria vaccine targeting both infection and transmission.
Versatope is leveraging extracellular vesicles to construct a universal influenza A vaccine candidate, VT-105, that provides durable immunity against multiple strains.
Versatope received a Phase 2 SBIR grant from NIH for up to $3 million to develop a bi-specific malaria vaccine targeting both infection and transmission.
Versatope is leveraging extracellular vesicles to construct a universal influenza A vaccine candidate, VT-105, that provides durable immunity against multiple strains.